NeoGenomics: Lynn Tetrault, Douglas Brown
NeoGenomics announced that it has appointed Lynn Tetrault as interim CEO and chair of the board of directors. Tetrault has been executive chair and principal executive officer of the company since March, when former CEO Mark Mallon stepped down, and has been overseeing the interim office of the CEO while NeoGenomics searches for a permanent CEO.
Tetrault has been a board member since 2015, was the lead independent director from 2020 to 2021, and was appointed nonexecutive chair in 2021. She previously served in a variety of roles at AstraZeneca, including EVP of human resources and corporate affairs. She is also a nonexecutive director of Rhythm Pharmaceuticals.
NeoGenomics also announced that Douglas Brown, its chief strategy and corporate development officer, will be leaving the firm on May 27.